FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

NHS Scotland to Reimburse for Revlimid With Dexamethasone for Multiple Myeloma

Dec. 16, 2015

NHS Scotland said it will list Celgene’s Revlimid in combination with dexamethasone for the treatment of adults with previously untreated multiple myeloma.

In addition, patients who are not eligible for stem cell transplant and are unsuitable for thalidomide-containing regimens can now receive Revlimid (lenalidomide).

Lenalidomide plus dexamethasone significantly improved progression-free survival in patients compared with those receiving melphalan-prednisone-thalidomide, with PFS medians amounting to 26 months and 21 months, respectively. The treatment also had a median overall survival of 58.9 months versus 48.5 months for patients treated with melphalan-prednisone-thalidomide.